| 王晓媛,徐梦园,彭 昭,卢书明,杨婕琳.马来酸曲美布汀联合莫沙必利对功能性消化不良患者胃电图参数、肠道菌群和血清NPSR-1、CGRP、MTL、GAS的影响[J].,2022,(10):1923-1927 |
| 马来酸曲美布汀联合莫沙必利对功能性消化不良患者胃电图参数、肠道菌群和血清NPSR-1、CGRP、MTL、GAS的影响 |
| Effects of Trimebutine Maleate Combined with Mosapride on Electrogastrogram Parameters, Intestinal Flora and Serum NPSR-1, CGRP, MTL and GAS in Patients with Functional Dyspepsia |
| 投稿时间：2021-11-08 修订日期：2021-11-25 |
| DOI：10.13241/j.cnki.pmb.2022.10.026 |
| 中文关键词: 马来酸曲美布汀 莫沙必利 功能性消化不良 胃电图参数 肠道菌群 神经肽S受体-1 降钙素基因相关肽 胃动素 |
| 英文关键词: Trimebutine maleate Mosapride Functional dyspepsia Electrogastrogram parameters Intestinal flora Neuropeptide S receptor-1 Calcitonin gene-related peptide Motilin |
| 基金项目:国家自然科学基金项目（81502274）；河北省卫健委青年科技课题（20190874） |
|
| 摘要点击次数: 726 |
| 全文下载次数: 367 |
| 中文摘要: |
| 摘要 目的：观察马来酸曲美布汀联合莫沙必利对功能性消化不良（FD）患者胃电图参数、肠道菌群和血清神经肽S受体-1（NPSR-1）、降钙素基因相关肽（CGRP）、胃动素(MTL)、胃泌素(GAS)的影响。方法：选取2019年8月~2021年6月期间我院收治的FD患者100例，根据信封抽签法分为对照组（莫沙必利治疗，n=50）和观察组（马来酸曲美布汀联合莫沙必利治疗，n=50）。对比两组疗效、胃电图参数、肠道菌群变化情况和血清NPSR-1、CGRP、MTL、GAS水平，记录两组不良反应发生率。结果：观察组的临床总有效率高于对照组（P<0.05）。治疗后，两组空腹及餐后正常慢波百分比均较治疗前升高，胃电频率、胃电紊乱节律百分比均较治疗前下降，且观察组的变化幅度更大（P<0.05）。治疗后，两组肠杆菌、肠球菌、酵母菌数量较治疗前下降，且观察组的下降幅度更明显（P<0.05）。治疗后，两组血清CGRP水平较治疗前下降，NPSR-1、MTL、GAS水平较治疗前升高，且观察组的变化幅度更大（P<0.05）。两组不良反应发生率组间对比差异无统计学意义（P>0.05）。结论：马来酸曲美布汀联合莫沙必利治疗FD患者，可有效改善胃电图参数和肠道菌群分布，调节其血清NPSR-1、CGRP、MTL、GAS水平，安全有效。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the effects of trimebutine maleate combined with mosapride on electrogastrogram parameters, intestinal flora, serum neuropeptide S receptor-1 (NPSR-1), calcitonin gene-related peptide (CGRP), motilin (MTL) and gastrin (GAS) in patients with functional dyspepsia (FD). Methods: 100 patients with FD who were treated in our hospital from August 2019 to June 2021 were. According to the envelope lottery method, the patients were divided into control group (mosapride treatment, n=50) and observation group (trimebutine maleate combined with mosapride treatment, n=50). The efficacy, electrogastrogram parameters, intestinal flora changes and serum NPSR-1, CGRP, MTL and GAS levels were compared between the two groups, and the incidence of adverse reactions in the two groups was recorded. Results: The total clinical effective rate in the observation group was higher than that in the control group (P<0.05). After treatment, the percentage of fasting and postprandial normal slow wave in the two groups increased compared with those before treatment, and the gastric electrical frequency and the percentage of gastric electrical disorder rhythm decreased compared with those before treatment, and the change range in the observation group was greater than that in the control group (P<0.05). After treatment, the number of enterobacter, enterococcus and yeast bacteria in two groups were decreased compared with those before treatment, and the decrease range in the observation group was more obvious (P<0.05). After treatment, the CGRP level in two groups was decreased compared with that before treatment, while the NPSR-1, MTL and GAS levels were increased compared with those before treatment, and the change range in the observation group was larger (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Trimebutine maleate combined with mosapride in the treatment of patients with FD can effectively improve the electrogastrogram parameters and intestinal microflora distribution, and regulate the NPSR-1, CGRP, MTL and GAS levels, which is safe and effective. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
